Transaction includes late-stage, potential best-in-class irreversible small molecule BTK inhibitor, acalabrutinib Opportunity for first regulatory submissions in haematological malignancies in 2016
Strategic alliance with WuXi AppTec to develop next-generation biologics in China New small molecule development facility; new global hub for Pharmaceutical Development
Acquisition to include non-US rights to roflumilast and will beaccretive to 2016 earnings, contributing to AstraZeneca’s return to growth strategy
Further to recent speculation, AstraZeneca confirms that it is exploring potential strategic options with Acerta Pharma BV. There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction.
The Company will make a further announcement if and when appropriate.
– ENDS –
NOTES TO EDITORS
About AstraZeneca
AstraZeneca is a global, inn
AstraZeneca och koncernens globala forsknings- och utvecklingsbolag för biologiska läkemedel, Medimmune, meddelar idag ett treårigt samarbete med det nybildade forskningscentret Wallenberg Centre for Protein Research (WCPR).
Divestmentfurther sharpens focus on three main therapy areas Agreement follows ex-US divestment of Entocort in July 2015
AstraZeneca and Sanofi today announced a direct exchange of 210,000 compounds from their respective proprietary compound libraries. The swap represents a novel open innovation model between pharmaceutical companies.
AstraZeneca today announced three new partnerships that will deliver industry-leading technologies to drive the AstraZeneca MRC UK Centre for Lead Discovery in the search for novel small molecule medicines. The partnerships will ensure state-of-the-art screening and compound management at the facility, which will be located within the company’s new global R&D centre at the Cambridge Biomedical
One of fastest development programmes – from start of clinical trials to approval in just over two and a half years to meet unmet patient need With objective response rate of 59% and duration of response of 12.4 months, TAGRISSO provides important new option for patients
BRO:s Utmärkelse 2015 tilldelas Helena Janlöv-Remnerud, sjuksköterska och medicinsk lymfterapeut, hemmahörande i Edsbro i Uppland.
Data presented at AHA suggests benefit in patients who stayed on Brilique (ticagrelor) treatment.
Anifrolumab met primary and secondary endpoints in Phase II, significantly reducing lupus disease activity compared with placebo across multiple endpoints
AstraZeneca to acquire ZS Pharma for $90 per share Acquisition includes potential best-in-class hyperkalaemia treatment currently under US FDA regulatory review
Pascal Soriot, koncernchef, kommenterar resultatet: "Jag är nöjd med framstegen vi gör. Vi fortsätter att fokusera på genomförandet av våra planer för tillväxtplattformarna och forskningsportföljen.
AstraZeneca and Eli Lilly and Company (Lilly) today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumours
AstraZeneca today announced the opening of its new state-of-the-art manufacturing and packaging facility in Kaluga, Russia, dedicated to the local supply of innovative medicines.
Läkemedelsverket har godkänt försäljning av Losec (omeprazol), ett läkemedel mot refluxsjukdom i svensk dagligvaruhandel. Det receptfria läkemedlet kommer att finnas tillgängligt på COOP, Willys, Hemköp och MatHem, samt på vissa bensinstationer runt om i landet.Losec är ett svenskt läkemedel som forskades fram av AstraZeneca i Göteborg.
AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for the investigational fixed-dose combination of saxagliptin and dapagliflozin for the treatment of adult patients with type 2 diabetes
AstraZenecas filmserie ”Grymt Fett” - om hur tonårshjärnan fungerar har blivit en succé i svenska skolor. Filmerna är det mest beställda materialet av lärare från beställningstjänsten Utbudet och har setts av fler än 250 000 elever.
The New England Journal of Medicine (NEJM) has published positive results from two pivotal, multi-centre, Phase III studies – AMAGINE-2 and AMAGINE-3 - demonstrating that treatment with brodalumab resulted in significant clinical improvements in patients with moderate to severe psoriasis and was superior to both placebo and ustekinumab, a leading approved treatment for psoriasis.